Inspire Medical Systems Awaits Q1 2025 Earnings Release

Published 21 hours agoINSP

Inspire Medical Systems Awaits Q1 2025 Earnings Release

As of May 2, 2025, Inspire Medical Systems has not yet released its earnings report for Q1 2025. Historically, the company announces its quarterly results about a month after the period ends, which suggests that investors can expect the report in early June 2025. This timing has see investors keen to understand how the company's recent financial growth trends will continue.

Inspire Medical's Q4 2024 results showed robust performance, with revenue reaching $239.7 million, marking a 25% increase compared to the previous year. The company also reported a gross margin of 85.0% and a net income of $35.2 million. The diluted earnings per share stood at $1.15. During the same quarter, Inspire activated 72 new U.S. centers, raising the total number to 1,435, and generated an operating cash flow of $69.2 million.

Looking at the full year 2024, Inspire posted a revenue of $802.8 million, a 28% rise from the previous year. The company is targeting a revenue range of $940 million to $955 million for 2025, indicating a 17% to 19% growth year-over-year. Inspire's guidance for diluted EPS is between $2.10 and $2.20. Reuters noted that these figures underscore the company's positive trajectory as stakeholders anticipate its forthcoming disclosures.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Insider Selling and Increased Short Interest at ON Semiconductor

Insider Selling and Increased Short Interest at ON Semiconductor

24 minutes agoON

ON Semiconductor Corporation has recently witnessed significant insider selling and a rise in short interest, raising concerns about investor sentiment toward the company. On March 12, 2025, Chairman Alan Campbell offloaded shares valued at around $432,257. This follows sales in December 2024 by CEO Hassane El-Khoury, who sold 1,500 shares for $105,000, and Group President Sudhir Gopalswamy, who sold 21,082 shares for $1.43 million. Alongside these sales, short interest in ON Semiconductor shares has climbed considerably. By February 28, 2025, short interest stood at 31.32 million shares, making up 7.48% of the company's float. This represents a 16.91% jump from the previous month's figures, as reported by Reuters, suggesting that more investors are betting against the stock. These actions come amid a period of investor scrutiny regarding ON Semiconductor's outlook. While insider sales and heightened short interest do not automatically equate to future performance issues, they do indicate a level of apprehension within the market and the company. These trends underscore the importance of monitoring insider and market behaviors closely.

ExxonMobil Exceeds Production Goals with Strong Q1 Earnings

ExxonMobil Exceeds Production Goals with Strong Q1 Earnings

55 minutes agoXOM

ExxonMobil has reported impressive financial performance in the first quarter of 2025, showcasing a stellar rise in earnings and production levels. The company's earnings reached $7.71 billion, driven by substantial increases in oil and gas production from key areas such as Guyana and the Permian Basin. This resulted in a remarkable total output of 4.55 million barrels of oil equivalent per day, significantly improved from 3.78 million barrels a year earlier. In a continued commitment to shareholder satisfaction, ExxonMobil distributed $4.3 billion in dividends while repurchasing $4.8 billion in shares, in line with its $20 billion annual buyback target. The company is also making notable investments in low-carbon technology, pledging $30 billion towards emissions reduction through technologies like carbon capture, biofuels, and more, establishing a clear lead over competitors BP and Shell. ExxonMobil's strategic acquisitions, including the $64.5 billion takeover of Pioneer Natural Resources, have boosted its footprint in the Permian Basin, promising enhanced returns. Since initiating its cost savings program in 2019, the company has accrued $12.1 billion in savings, demonstrating significant operational efficiency. According to Reuters, these strategic moves ensure that ExxonMobil remains a dominant force within the oil industry.

Gilead and Vertex: Navigating Tariff Challenges with Strategic Plans

Gilead and Vertex: Navigating Tariff Challenges with Strategic Plans

1 hours agoGILD

Gilead Sciences and Vertex Pharmaceuticals have garnered attention in the biotech sector for their robust strategies amidst global trade disruptions. Although specific recognition as 'tariff safe havens' isn't documented, their operational approaches position them well to withstand tariff challenges impacting the industry. Both companies have established diverse manufacturing operations around the world, enabling them to adapt to varied trade policies and mitigate direct impacts from tariffs. Additionally, Gilead and Vertex source key raw materials from different countries, minimizing dependency on any single market. This supply chain diversification lessens their vulnerability to sudden changes in trade dynamics. Furthermore, Gilead and Vertex engage in strategic partnerships with international firms, promoting market access and broadening distribution channels. By adapting to different regulatory environments, they ensure compliance and continued operations despite potential trade barriers. These strategies underscore their proactive measures to navigate the complexities of global trade.

Significant Insider Selling Hits Chewy, Inc.

Significant Insider Selling Hits Chewy, Inc.

2 hours agoCHWY

Recent movements in Chewy, Inc.'s stock have drawn attention as significant insider sales have been made by prominent figures associated with the online pet supply giant. Keith Gill, famously known as 'Roaring Kitty', sold his entire 6.6% stake in Chewy, which amounts to about 9 million shares. This large sell-off contributed to nearly a 2% dip in the company's stock price, as noted by Reuters. In addition to Gill's exit, other key insiders have also sold off substantial amounts of their shares. On February 7, 2025, Chewy's CFO, David Reeder, sold 307,558 shares at an average price of $37.48, yielding approximately $11.5 million. Furthermore, CEO Sumit Singh offloaded a total of 642,225 shares between December 19 and December 26, 2024, at prices ranging from $32.50 to $35.00, accounting for over $24 million in sales. Another major sale occurred on October 15, 2024, when Argos Holdings GP LLC sold 1,250,000 shares at $29.40 each, totaling about $36.75 million. While these insider sales may suggest waning confidence in Chewy's immediate future, it is crucial to consider that such decisions can often be driven by personal financial strategies. These transactions highlight the complexities of interpreting insider activity, as noted by various publications such as Reuters and the Associated Press.